Revenue: As of FY2025 Q4, the actual value is USD 263.62 M, beating the estimate of USD 259.59 M.EPS: As of FY2025 Q4, the actual value is USD 1.21, beating the estimate of USD 1.175.EBIT: As of FY2025 Q4, the actual value is USD 52.29 M.<h4>Fourth Quarter 2025 Financial Performance</h4><ul><li>Net Earnings: GAAP net earnings were $39.2 million, marking a 16.8% increase compared to the prior year quarter. Adjusted net earnings were $42.338 million, up from $36.876 million in the prior year quarter .</li><li>Adjusted EBITDA: Adjusted EBITDA reached $67.9 million, an 8.1% increase from the prior year quarter .</li><li>Gross Margin: Consolidated quarterly gross margin was $93.9 million, an increase of 8.8% compared to $86.3 million in the prior year period. Gross margin as a percentage of sales decreased by 40 basis points to 35.6% from 36.0% in the prior year period, primarily due to higher manufacturing input costs .</li><li>Operating Expenses: Operating expenses for the quarter were $41.6 million, an increase of $2.7 million from the prior year comparable quarter, mainly due to higher compensation-related expenses. Excluding non-cash amortization of intangible assets, operating expenses were $38.0 million, or 14.4% of sales .</li><li>Net Interest Expense: Net interest expense was $1.9 million, down from $2.8 million in the prior year quarter, attributed to lower outstanding borrowings and interest rates .</li><li>Effective Tax Rate: The effective tax rate for the quarter was 21.6%, a decrease from 24.5% in the prior year, primarily due to a decrease in certain foreign taxes .</li><li>Cash Flow: Cash flows from operations were $67.3 million, and free cash flow was $51.2 million .</li></ul><h4>Full Year 2025 Financial Performance</h4><ul><li>Net Earnings: GAAP net earnings were $154.8 million, representing a 20.5% increase from the prior year. Adjusted net earnings were $167.9 million, an increase of 17.4% from the prior year .</li><li>Adjusted EBITDA: Adjusted EBITDA was $274.9 million, a 9.8% increase from the prior year .</li><li>Cash Flow: Cash flows from operations were $216.6 million, and free cash flow was $173.6 million .</li></ul><h4>Fourth Quarter 2025 Segment Revenue</h4><ul><li>Human Nutrition and Health: Sales were $166.1 million, an increase of $18.8 million or 12.7% compared to the prior year quarter, driven by higher sales in both nutrients and food ingredients businesses .</li><li>Animal Nutrition and Health: Sales were $61.2 million, an increase of $2.8 million or 4.9% compared to the prior year quarter, due to higher sales in ruminant and monogastric species markets .</li><li>Specialty Products: Sales were $34.8 million, an increase of $2.0 million or 6.0% compared to the prior year quarter, driven by higher sales in the performance gases business .</li><li>Other: Sales were $1.544 million .</li></ul><h4>Fourth Quarter 2025 Segment Earnings from Operations</h4><ul><li>Human Nutrition and Health: Earnings from operations were $36.8 million, an 8.9% increase, primarily due to higher sales and a favorable mix. Adjusted earnings from operations were $40.0 million, an increase of 9.6% .</li><li>Animal Nutrition and Health: Earnings from operations were $6.2 million, an 8.6% increase, primarily due to higher sales and a favorable mix. Adjusted earnings from operations were $6.5 million, an increase of 9.2% .</li><li>Specialty Products: Earnings from operations were $10.5 million, a 5.5% increase, driven by higher sales. Adjusted earnings from operations were $11.6 million, an increase of 6.0% .</li><li>Other and Unallocated: Earnings from operations were - $1.206 million .</li></ul><h4>Balance Sheet and Cash Flow Activities (as of December 31, 2025)</h4><ul><li>Net Working Capital: Net working capital was $189.2 million .</li><li>Cash and Cash Equivalents: Cash balance was $74.6 million .</li><li>Outstanding Debt: Outstanding debt on the revolving loan was $164.0 million .</li><li>Net Debt: Net debt was $89.4 million, with an overall leverage ratio of 0.3 times on a net debt basis .</li><li>Significant Cash Payments (Q4): During the quarter, significant cash payments included $53.6 million for common stock repurchases, $16.2 million for capital expenditures and intangible assets acquired, and $8.1 million for income taxes paid .</li><li>Full Year Cash Flow Activities: Net cash used in investing activities was - $43.891 million. Net cash used in financing activities was - $152.810 million, including principal payments on revolving debt of - $114.0 million, dividends paid of - $28.287 million, and repurchases of common stock of - $107.636 million .</li></ul><h4>Outlook</h4>拜切公司 (Balchem Corporation) anticipates continued strong performance and expects ongoing above-market growth for shareholders in 2026 and beyond. The company’s leadership expressed excitement about the future and its strong positioning .

Balchem | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 263.62 M